Lixisenatide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Lixisenatide: From Type 2 Diabetes Mellitus to Opsismodysplasia
One-Sentence Summary
Lixisenatide is a GLP-1 receptor agonist originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for opsismodysplasia, a rare skeletal dysplasia, but no clinical trials and no publications currently support this direction. The prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus (the licence records list no approved indication text, so this comes from the knowledge graph) |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 97.56% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, lixisenatide is a GLP-1 receptor agonist that acts on incretin signalling. Its efficacy in type 2 diabetes mellitus is established, but no mechanistic link to opsismodysplasia has been shown.
Opsismodysplasia is a rare skeletal dysplasia caused by INPPL1 mutations, which affect SHIP2 signalling and growth plate development. Incretin signalling is not known to act on this pathway. The high score (0.976) is a knowledge-graph prediction only, so it should be read as a hypothesis-generating signal rather than evidence of benefit.
Other top-ranked predictions show the same pattern. These include focal stiff limb syndrome, classic stiff person syndrome, thiamine-responsive dysfunction syndrome and several localized lipodystrophies. Their links to lixisenatide look driven by shared diabetes or metabolic neighbours in the graph, not by pharmacology. None has supporting trials or literature.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for opsismodysplasia.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15540P | SOLIQUA Solution for Injection in a Pre-filled Pen 100 units/mL + 50 mcg/mL | Injection, solution | Not stated in the data compiled |
| SIN15542P | SOLIQUA Solution for Injection in a Pre-filled Pen 100 units/mL + 33 mcg/mL | Injection, solution | Not stated in the data compiled |
Both licences are held by Sanofi-Aventis Deutschland GmbH and are currently valid. The route of administration is injectable.
Safety Considerations
- Drug Interactions: The interaction screen returned 100 potential interactions. The first 20 reviewed are mostly Moderate, with a few Minor. Notable Moderate examples include:
- Sympathomimetics and bronchodilators: phenylephrine, pseudoephedrine, epinephrine, salbutamol, formoterol
- Corticosteroids: hydrocortisone, triamcinolone
- Hormonal agents: ethinylestradiol, estradiol, norethisterone, desogestrel
- Others: acetazolamide, hydrochlorothiazide, ethanol, alpelisib, aripiprazole, asenapine, asparaginase
Minor examples are topical hydrocortisone and topical alclometasone.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score. There are no trials, no literature and no plausible mechanistic link between GLP-1 receptor agonism and INPPL1/SHIP2-driven skeletal dysplasia. Evidence is at level L5.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (HSA), which are needed for safety screening
- Mechanism of action data for lixisenatide
- Preclinical or mechanistic evidence connecting GLP-1 signalling to growth plate biology or SHIP2 pathways
- A review of whether any other predicted indication has a stronger rationale; all ten in this set are currently at L4 or L5 with a Hold recommendation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.